BLASINGLE-USEVIAL1 Generic Approved
Approved
Feb 2026
Lifecycle
Launch
Competitive Pressure
30/100
Data completeness
2/8 — Basic
RYBREVANT FASPRO (amivantamab and hyaluronidase-lpuj (human recombinant)) by Johnson & Johnson. Approved for endoglycosidase [epc]. First approved in 2026.
Drug data last refreshed 23h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
RYBREVANT FASPRO is a bispecific antibody (amivantamab) combined with hyaluronidase for subcutaneous delivery, designed to target multiple cancer pathways via endoglycosidase mechanism. The hyaluronidase component enables faster subcutaneous administration by breaking down hyaluronic acid in subcutaneous tissue. This combination offers improved patient convenience and dosing flexibility compared to traditional IV formulations.
Launch
Early-stage launch phase indicates active commercial team expansion with emphasis on field force training, payer education, and market penetration strategies.
Mechanism of Action
Pharmacologic Class:
Endoglycosidase
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on RYBREVANT FASPRO offers exposure to bispecific antibody development, regulatory strategy, and quality/manufacturing excellence at a high-profile Johnson & Johnson launch. Career growth is strong in R&D, legal, and QA functions, with 8 actively linked roles reflecting active team building.
ScientistDirector
Worked on RYBREVANT FASPRO at Johnson & Johnson? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.